Joe McCann, Point Biopharma CEO
Just months after SPAC reverse merger, Point Biopharma ups the ante at Indianapolis manufacturing site
Point Biopharma trotted out to near-unicorn status in March as part of a reverse merger with a SPAC backed by RA Capital’s Peter Kolchinsky …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
